[Clinical trial of the Bulgarian digitalis preparation, Digilanide C used intravenously].
The Bulgarian digitalis preparation Digilanid C for venous application has a satisc factory effect on the majority of the patients (67 per cent) with light and moderate chronic cardia insufficiency and espically in case of tachycardia in auricular fibrillation. The comparison of the results between the group of 46 patients, treated with Digilanid C and the control group of 20 patients treated with Isolanid (Richter) do not reveal essential differences in the major part of the results obtained.
D000328:Adult; D000368:Aged; D002031:Bulgaria; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007275:Injections, Intravenous; D007799:Lanatosides / Q000506:poisoning / Q000627:therapeutic use*; D008875:Middle Aged; D012214:Rheumatic Heart Disease / Q000188:drug therapy; D013610:Tachycardia / Q000188:drug therapy
D007799:Lanatosides
Klinichno izpitvane na bulgarskiia digitalisov preparat Digilanid C za venozno prilozhenie